*4.3.3 FGFR*

Fibroblast growth factor receptors (FGFRs) are a subfamily of RTKs occurring in approximately 3–5% of CRC patients [112]. Initial evidence shows poor outcomes associated with FGFR3 alterations [120]. There is no evidence of clinicopathological characteristics related to these alterations [120].

Regorafenib, a multi-kinase inhibitor also targeting FGFR, is currently approved by the FDA for metastatic CRC patients who progressed on frontline therapies. This agent can be considered in CRC patients with FGFR alterations while novel FGFR inhibitors are not available [121]. Newly developed, more potent FGFR inhibitors are currently being investigated in multiple solid tumors [112].
